Skip to main content

Advertisement

SpringerLink
Log in

Endothelin B receptor agonist, IRL 1620, enhances the anti-tumor efficacy of paclitaxel in breast tumor rats

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

Pharmacological agents that increase tumor blood flow could be utilized to promote the delivery of anti-cancer drugs. We have demonstrated that administration of endothelin-1 (ET-1) to breast tumor bearing rats transiently increased tumor blood flow by stimulating endothelin B (ETB) receptors. The present study evaluated the effect of ETB receptor agonist, IRL 1620, on breast tumor perfusion, concentration of [3H]paclitaxel in tumor and tissues, and efficacy of paclitaxel in N-methyl nitrosourea induced breast tumor bearing rats. Administration of IRL 1620 (3 and 9 nmol/kg) significantly increased (203 and 140%, respectively) breast tumor perfusion. BQ 788, an ETB receptor antagonist, pretreatment completely abolished IRL 1620 induced increase in tumor perfusion. Tumor [3H]paclitaxel concentration was increased by 308% when [3H]paclitaxel was administered 15 min after IRL 1620 (3 nmol/kg) compared to vehicle treated rats. However, IRL 1620 did not increase [3H]paclitaxel concentrations in other organs. Efficacy study showed that paclitaxel (5 mg/kg) administration on every third day for a total of five doses produced 60.0, 4.5 and 0% reduction in tumor volume, tumor progression and complete tumor remission, respectively, compared to saline treated rats. However, paclitaxel (5 mg/kg) when administered 15 min after IRL 1620 (3 nmol/kg) produced 268.9, 210.3 and 20% reduction in tumor volume, tumor progression and complete remission of tumors, respectively, compared to saline treated rats. In conclusion, IRL 1620 significantly enhanced delivery and effectiveness of paclitaxel in an animal model of breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ, (2005) Cancer statistics, 2005 CA Cancer J Clin 55: 10–30

    PubMed  Google Scholar 

  2. Jain RK, (1990) Vascular and interstitial barriers to delivery of therapeutic agents in tumors Cancer Metast Rev 9: 253–266

    Article  CAS  Google Scholar 

  3. Jain RK, (1991) Haemodynamic and transport barriers to the treatment of solid tumours Int J Radiat Biol 60: 85–100

    Article  PubMed  CAS  Google Scholar 

  4. Hahn SM, Liebmann JE, Cook J, Fisher J, Goldspiel B, Venzon D, Mitchell JB, Kaufman D, (1993) Taxol in combination with doxorubicin or etoposide Possible antagonism in vitro Cancer 72: 2705–2711

    Article  PubMed  CAS  Google Scholar 

  5. Tolcher AW, (1996) Paclitaxel couplets with cyclophosphamide or cisplatin in metastatic breast cancer Semin Oncol 23: 37–43

    PubMed  CAS  Google Scholar 

  6. Fornier M, Esteva FJ, Seidman AD: Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer. Semin Oncol 27: 38–45, 2000 discussion 92–100

    Google Scholar 

  7. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T, (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells Nature 332: 411–415

    Article  PubMed  CAS  Google Scholar 

  8. Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, Masaki T, (1989) The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes Proc Natl Acad Sci USA 86: 2863–2867

    Article  PubMed  CAS  Google Scholar 

  9. de Nucci G, Thomas R, D’Orleans-Juste P, Antunes E, Walder C, Warner TD, Vane JR, (1988) Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor Proc Natl Acad Sci USA 85: 9797–9800

    Article  PubMed  Google Scholar 

  10. Jain RK, (1988) Determinants of tumor blood flow: a review Cancer Res 48: 2641–2658

    PubMed  CAS  Google Scholar 

  11. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, Jain RK, McDonald DM, (2000) Openings between defective endothelial cells explain tumor vessel leakiness Am J Pathol 156: 1363–1380

    PubMed  CAS  Google Scholar 

  12. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E, (1999) Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal J Clin Invest 103: 159–165

    PubMed  CAS  Google Scholar 

  13. Helmlinger G, Endo M, Ferrara N, Hlatky L, Jain RK, (2000) Formation of endothelial cell networks Nature 405: 139–141

    Article  PubMed  CAS  Google Scholar 

  14. Jain RK, (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy Nat Med 7: 987–989

    Article  PubMed  CAS  Google Scholar 

  15. Okada M, Nishikibe M, (2002) BQ-788, a selective endothelin ET(B) receptor antagonist Cardiovasc Drug Rev 20: 53–66

    Article  PubMed  CAS  Google Scholar 

  16. Rai A, Gulati A, (2003) Evidence for the involvement of ET(B) receptors in ET-1-induced changes in blood flow to the rat breast tumor Cancer Chemother Pharmacol 51: 21–28

    Article  PubMed  CAS  Google Scholar 

  17. Takai M, Umemura I, Yamasaki K, Watakabe T, Fujitani Y, Oda K, Urade Y, Inui T, Yamamura T, Okada T, (1992) A potent and specific agonist, Suc-[Glu9,Ala11,15]-endothelin-1(8–21), IRL 1620, for the ETB receptor Biochem Biophys Res Commun 184: 953–959

    Article  PubMed  CAS  Google Scholar 

  18. Rajeshkumar NV, Rai A, Green A, Gionetti G, Das Gupta TK, Gulati A: Endothelin B receptor agonist, IRL 1620, increases blood perfusion and enhances paclitaxel delivery to tumor. In: 96th AACR annual meeting, Anaheim, CA, pp. 1349, abstract # 5741, 2005

  19. Rai A, Rajeshkumar NV, Gulati A: Enhanced delivery of paclitaxel selectively to the breast tumor tissue by Endothelin B receptor agonist. In: AAPS-PDD Conference, Philadelphia, PA, pp. 62, abstract # 1018, 2004

  20. Gulati A, Rai A, Rajeshkumar NV: ET B receptor agonist, IRL 1620, enhances the efficacy of paclitaxel in reducing breast tumor volumes in rats. In: 96th AACR annual meeting, Anaheim, CA, pp. 338, abstract # 1443, 2005

  21. Rai A, Rajeshkumar NV, Shord S, Gulati A, (2005) Endothelin B receptor agonist, IRL 1620, does not affect paclitaxel plasma pharmacokinetics in breast tumor bearing rats J Pharm Pharmacol (in press)

    Article  PubMed  CAS  Google Scholar 

  22. Mehta RG, (2000) Experimental basis for the prevention of breast cancer Eur J Cancer 36: 1275–1282

    Article  PubMed  CAS  Google Scholar 

  23. Klecker RW, Jamis-Dow CA, Egorin MJ, Erkmen K, Parker RJ, Stevens R, Collins JM, (1994) Effect of cimetidine, probenecid, and ketoconazole on the distribution, biliary secretion, and metabolism of [3H]taxol in the Sprague-Dawley rat Drug Metab Dispos 22: 254–258

    PubMed  CAS  Google Scholar 

  24. Kim SC, Kim DW, Shim YH, Bang JS, Oh HS, Wan Kim S, Seo MH, (2001) In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy J Control Release 72: 191–202

    Article  PubMed  CAS  Google Scholar 

  25. Yen WC, Prudente RY, Lamph WW, (2004) Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma Breast Cancer Res Treat 88: 141–148

    Article  PubMed  CAS  Google Scholar 

  26. Bischoff ED, Heyman RA, Lamph WW, (1999) Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure J Natl Cancer Inst 91: 2118

    Article  PubMed  CAS  Google Scholar 

  27. Brooks DP, DePalma PD, Pullen M, Gellai M, Nambi P: Identification and function of putative ETB receptor subtypes in the dog kidney J Cardiovasc Pharmacol 26(Suppl 3): S322–S325

  28. Sudjarwo SA, Hori M, Tanaka T, Matsuda Y, Okada T, Karaki H, (1994) Subtypes of endothelin ETA and ETB receptors mediating venous smooth muscle contraction Biochem Biophys Res Commun 200: 627–633

    Article  PubMed  CAS  Google Scholar 

  29. Bell KM, Chaplin DJ, Poole BA, Prise VE, Tozer GM, (1999) Modification of blood flow in the HSN tumour and normal tissues of the rat by the endothelin ET(B) receptor agonist, IRL 1620 Int J Cancer 80: 295–302

    Article  PubMed  CAS  Google Scholar 

  30. Bell KM, Prise VE, Chaplin DJ, Tozer GM, (1996) Tumour blood flow modification by endothelin-related peptides in the rat HSN fibrosarcoma Br J Cancer Suppl 27: S161–S163

    PubMed  CAS  Google Scholar 

  31. Buchsbaum DJ, Zhou T, Grizzle WE, Oliver PG, Hammond CJ, Zhang S, Carpenter M, LoBuglio AF, (2003) Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model Clin Cancer Res 9: 3731–3741

    PubMed  CAS  Google Scholar 

  32. Emanuel S, Gruninger RH, Fuentes-Pesquera A, Connolly PJ, Seamon JA, Hazel S, Tominovich R, Hollister B, Napier C, D’Andrea MR, Reuman M, Bignan G, Tuman R, Johnson D, Moffatt D, Batchelor M, Foley A, O’Connell J, Allen R, Perry M, Jolliffe L, Middleton SA, (2004) A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models Mol Pharmacol 66: 635–647

    Article  PubMed  CAS  Google Scholar 

  33. DeCosse JJ, Gossens C, Kuzma JF, Unsworth BR, (1975) Embryonic inductive tissues that cause histologic differentiation of murine mammary carcinoma in vitro J Natl Cancer Inst 54: 913–922

    PubMed  CAS  Google Scholar 

  34. Bissell MJ, Radisky D, (2001) Putting tumours in context Nat Rev Cancer 1: 46–54

    Article  PubMed  CAS  Google Scholar 

  35. Lhuillery C, Bougnoux P, Groscolas R, Durand G, (1995) Time-course study of adipose tissue fatty acid composition during mammary tumor growth in rats with controlled fat intake Nutr Cancer 24: 299–309

    Article  PubMed  CAS  Google Scholar 

  36. Russo J, Gusterson BA, Rogers AE, Russo IH, Wellings SR, van Zwieten MJ, (1990) Comparative study of human and rat mammary tumorigenesis Lab Invest 62: 244–278

    PubMed  CAS  Google Scholar 

  37. Harris CC, Hirohashi S, Ito N, Pitot HC, Sugimura T, Terada M, Yokota J, (1992) Multistage carcinogenesis: the Twenty-Second International Symposium of the Princess Takamatsu Cancer Research Fund Cancer Res 52: 4837–4840

    PubMed  CAS  Google Scholar 

  38. Zee-Cheng RK, Cheng CC, (1989) Delivery of anticancer drugs Methods Find Exp Clin Pharmacol 11: 439–529

    PubMed  CAS  Google Scholar 

  39. Carmeliet P, Jain RK, (2000) Angiogenesis in cancer and other diseases Nature 407: 249–257

    Article  PubMed  CAS  Google Scholar 

  40. Jirtle RL, (1988) Chemical modification of tumour blood flow Int J Hyperther 4: 355–371

    CAS  Google Scholar 

  41. Chaplin DJ, Hill SA, Bell KM, Tozer GM, (1998) Modification of tumor blood flow: current status and future directions Semin Radiat Oncol 8: 151–163

    Article  PubMed  CAS  Google Scholar 

  42. Jordan BF, Misson P, Demeure R, Baudelet C, Beghein N, Gallez B, (2000) Changes in tumor oxygenation/perfusion induced by the no donor, isosorbide dinitrate, in comparison with carbogen: monitoring by EPR and MRI Int J Radiat Oncol Biol Phys 48: 565–570

    Article  PubMed  CAS  Google Scholar 

  43. Fukumura D, Yuan F, Endo M, Jain RK, (1997) Role of nitric oxide in tumor microcirculation. Blood flow, vascular permeability, and leukocyte-endothelial interactions Am J Pathol 150: 713–725

    PubMed  CAS  Google Scholar 

  44. Hirst DG, Kennovin GD, Flitney FW, (1994) The radiosensitizer nicotinamide inhibits arterial vasoconstriction Br J Radiol 67: 795–799

    Article  PubMed  CAS  Google Scholar 

  45. Blezinger P, Wang J, Gondo M, Quezada A, Mehrens D, French M, Singhal A, Sullivan S, Rolland A, Ralston R, Min W, (1999) Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene Nat Biotechnol 17: 343–348

    Article  PubMed  CAS  Google Scholar 

  46. Wang Y, Becker D, (1997) Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth Nat Med 3: 887–893

    Article  PubMed  CAS  Google Scholar 

  47. Takeshita S, Tsurumi Y, Couffinahl T, Asahara T, Bauters C, Symes J, Ferrara N, Isner JM, (1996) Gene transfer of naked DNA encoding for three isoforms of vascular endothelial growth factor stimulates collateral development in vivo Lab Invest 75: 487–501

    PubMed  CAS  Google Scholar 

  48. Kerbel RS, (1991) Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents Bioessays 13: 31–36

    Article  PubMed  CAS  Google Scholar 

  49. Blagosklonny MV, (2004) Antiangiogenic therapy and tumor progression Cancer Cell 5: 13–17

    Article  PubMed  CAS  Google Scholar 

  50. Bottaro DP, Liotta LA, (2003) Cancer: out of air is not out of action Nature 423: 593–595

    Article  PubMed  CAS  Google Scholar 

  51. Steeg PS, (2003) Angiogenesis inhibitors: motivators of metastasis? Nat Med 9: 822–823

    Article  PubMed  CAS  Google Scholar 

  52. Semenza GL, (2002) HIF-1 and tumor progression: pathophysiology and therapeutics Trends Mol Med 8: S62–67

    Article  PubMed  CAS  Google Scholar 

  53. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM, (2003) Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene Cancer Cell 3: 347–361

    Article  PubMed  Google Scholar 

  54. Jain RK, (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307: 58–62

    Article  PubMed  CAS  Google Scholar 

  55. Ben-Baruch G, Schiff E, Galron R, Menczer J, Sokolovsky M, (1993) Impaired binding properties of endothelin-1 receptors in human endometrial carcinoma tissue Cancer 72: 1955–1958

    Article  PubMed  CAS  Google Scholar 

  56. Wulfing P, Diallo R, Kersting C, Wulfing C, Poremba C, Rody A, Greb RR, Bocker W, Kiesel L, (2003) Expression of endothelin-1, endothelin-A, and endothelin-B receptor in human breast cancer and correlation with long-term follow-up Clin Cancer Res 9: 4125–4131

    PubMed  Google Scholar 

  57. Wulfing P, Diallo R, Kersting C, Wulfing C, Poremba C, Greb RR, Bocker W, Kiesel L, (2004) Endothelin-1, Endothelin-A- and Endothelin-B-receptor expression in preinvasive and invasive breast disease Oncol Rep 11: 791–796

    PubMed  Google Scholar 

  58. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, Radmacher M, Simon R, Yakhini Z, Ben-Dor A, Sampas N, Dougherty E, Wang E, Marincola F, Gooden C, Lueders J, Glatfelter A, Pollock P, Carpten J, Gillanders E, Leja D, Dietrich K, Beaudry C, Berens M, Alberts D, Sondak V, (2000) Molecular classification of cutaneous malignant melanoma by gene expression profiling Nature 406: 536–540

    Article  PubMed  CAS  Google Scholar 

  59. Lahav R, Suvaml, Rimoldi D, Patterson PH, Stamenkovic I, (2004) Endothelin receptor B inhibition triggers apoptosis and enhances angiogenesis in melanomas Cancer Res 64: 8945–8953

    Article  PubMed  CAS  Google Scholar 

  60. Jimeno A, Carducci M, (2004) Atrasentan: targeting the endothelin axis in prostate cancer Expert Opin Investig Drugs 13: 1631–1640

    Article  PubMed  CAS  Google Scholar 

  61. Bagnato A, Natali PG, (2004) Targeting endothelin axis in cancer Cancer Treat Res 119: 293–314

    Article  PubMed  CAS  Google Scholar 

  62. Asham E, Shankar A, Loizidou M, Fredericks S, Miller K, Boulos PB, Burnstock G, Taylor I, (2001) Increased endothelin-1 in colorectal cancer and reduction of tumour growth by ET(A) receptor antagonism Br J Cancer 85: 1759–1763

    Article  PubMed  CAS  Google Scholar 

  63. Nelson J, Bagnato A, Battistini B, Nisen P, (2003) The endothelin axis: emerging role in cancer Nat Rev Cancer 3: 110–116

    Article  PubMed  CAS  Google Scholar 

  64. Sonveaux P, Dessy C, Martinive P, Havaux X, Jordan BF, Gallez B, Gregoire V, Balligand JL, Feron O, (2004) Endothelin-1 is a critical mediator of myogenic tone in tumor arterioles: implications for cancer treatment Cancer Res 64: 3209–3214

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgement

The authors are grateful to Mr George Matwyshyn for␣excellent technical assistance in mammary tumor induction. The work was supported by a grant from Chicago Labs Inc., Chicago, IL.

Author information

Authors and Affiliations

  1. Department of Biopharmaceutical Sciences, University of Illinois at Chicago, 833 South Wood Street, Chicago, IL, 60612, USA

    N.V. Rajeshkumar, Aarati Rai & Anil Gulati

Authors
  1. N.V. Rajeshkumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aarati Rai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anil Gulati
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anil Gulati.

Additional information

Address for offprints and correspondence: Anil Gulati, MD, PhD, Department of Biopharmaceutical Sciences (M/C 865), University of Illinois at Chicago, 833 South Wood Street, Chicago, IL 60612, USA; Tel.: +1-312-996-0826; Fax: +1-312-996-0098; E-mail: gulati@uic.edu

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rajeshkumar, N., Rai, A. & Gulati, A. Endothelin B receptor agonist, IRL 1620, enhances the anti-tumor efficacy of paclitaxel in breast tumor rats. Breast Cancer Res Treat 94, 237–247 (2005). https://doi.org/10.1007/s10549-005-9000-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-005-9000-3

Keywords

Search

Navigation